Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation [3]

Schizophrenia Research

Volumn 76, Issue 1, 2005, Pages 127-129

  Volavka, Jan ^a   Nolan, Karen A ^a   Kline, Linda ^a   Czobor, Pal ^a   Citrome, Leslie ^a   Sheitman, Brian ^b   Lindenmayer, Jean Pierre ^c   McEvoy, Joseph ^d   Lieberman, Jeffrey A ^e  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Dorothea Dix Hospital   (United States)

^c MANHATTAN PSYCHIATRIC CENTER   (United States)

^d John Umstead Hospital   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HOSPITAL PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOUBLE-BLIND METHOD; HALOPERIDOL; HUMANS; NURSING ASSESSMENT; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 20444450451     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.11.007     Document Type: Letter

References (3)

1. G. Honigfeld Nosie-30: history and current status of its use in pharmacopsychiatric research Mod. Probl. Pharmacopsychiatry 7 1974 238 263
2. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
3. J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. McEvoy, T.B. Cooper, M. Chakos, and J.A. Lieberman Clozapine, olanzapine, risperidone, and haloperidol in treatment-resistant patients with schizophrenia and schizoaffective disorder Am. J. Psychiatry 159 2002 255 262